A Versatile Complement Therapy Across Ocular, Hematologic, Renal, Dermatological, and Inflammatory Disorders. Key Highlights Commercial ...
Biogen’s acquisition of Apellis highlights interest in complement-based ophthalmology and multi-indication platforms. NM5072 represents a broad multi-indication opportunity, supported by preclinical ...
The last time I spoke about Omeros Corporation (OMER) it was in a Seeking Alpha article entitled "Omeros: FDA Appeal On Nasoplimab And Several 2023 Catalysts On Deck." Since then, it has faced several ...
Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
RG-6299 targets major unmet need in IgA nephropathy with a differentiated monthly antisense therapy. Promising clinical data, global Phase III development and strong partnerships support adoption, ...
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks, with s ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...
SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...
Mannose-binding lectin (MBL) is a soluble C-type lectin that recognises carbohydrate patterns on a wide range of pathogens and initiates the lectin pathway of complement activation. Upon binding to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results